Am J Health Syst Pharm. 2006;63(11):1022-1028. Q: How can potential medication errors be minimized when dispensing investigational drugs to better ensure patient safety and improve adherence to ...

The designation will provide Lundbeck with the possibility of rolling reviews and detailed guidance to streamline the drug ...

Amlenetug received Orphan Drug Designation (ODD) from the US FDA in April 2024, the EMA in May 2021 and SAKIGAKE designation ...

H. Lundbeck A/S (Lundbeck) today announced that amlenetug has received Fast Track designation from the United States (US) Food and Drug Administration (FDA).

Ac-SSO110 has now received FDA orphan drug designation and investigational new drug application clearance for the treatment ...

Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...

WashU Medicine-led trial evaluating investigational drug from Eli Lilly and Company aims to stop disease before symptoms arise Researchers at Washington University School of Medicine in St. Louis have ...

The FDA has granted Fast Track Designation to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).

MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...

RenovoRx (NASDAQ: RNXT) , a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath(R), a novel, FDA-cleare ...

Fabry Disease Clinical Trial Pipeline Major pharmaceutical companies are working to advance the pipeline space and unlock the future growth ...